Orient Technologies (NSE: ORIENTTECH) Q3 FY26 results: Why short-term margin pain may be the price of securing long-cycle government and services revenue
Read More 6 minute read Healthcare Industry News GRAIL (Nasdaq: GRAL) files FDA application for Galleri test, aiming to redefine how cancer is detected in asymptomatic patients GRAIL files FDA approval for Galleri, its blood-based test for early cancer detection. Find out what it means for diagnostics, payers, and public health. bySrinathJanuary 30, 2026